Mycopathologia, Год журнала: 2023, Номер 188(6), С. 1041 - 1053
Опубликована: Окт. 20, 2023
Язык: Английский
The Lancet Infectious Diseases, Год журнала: 2024, Номер 24(7), С. e428 - e438
Опубликована: Янв. 21, 2024
Язык: Английский
Процитировано
486
Open Forum Infectious Diseases, Год журнала: 2022, Номер 9(12)
Опубликована: Дек. 1, 2022
Fungal disease is frequent in India, but its incidence and prevalence are unclear. This review aims at defining the frequency or burden of various fungal infections India.
Язык: Английский
Процитировано
43
Therapeutic Advances in Infectious Disease, Год журнала: 2024, Номер 11
Опубликована: Янв. 1, 2024
It is of utmost importance to monitor any change in the epidemiology fungal diseases that may arise from a number at-risk population or availability local data.
Язык: Английский
Процитировано
11
Journal of Investigative Medicine High Impact Case Reports, Год журнала: 2025, Номер 13
Опубликована: Март 1, 2025
Co-infection with Mycobacterium tuberculosis and Aspergillus in an immunocompetent host is rare but can occur. In this case, we present a patient central nervous system (TB) biopsy-proven spinal co-infections TB Aspergillosis. We highlight the complexities of treating TB-Aspergillosis co-infection given drug-drug interactions between standard therapy for both conditions. Using susceptibilities carefully monitoring drug levels antifungal agents, were able to optimally treat co-infection. This was ultimately discharged on isoniazid 1200 mg (15 mg/kg) daily, levofloxacin 750 rifabutin 450 posaconazole 300 twice daily tentative plan at least 1 year close outpatient follow-up. case serve as guide other providers who need cases Aspergillosis by learning from our experience paying attention potential pitfalls.
Язык: Английский
Процитировано
1
The Lancet Infectious Diseases, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 1, 2024
Язык: Английский
Процитировано
7
Mycopathologia, Год журнала: 2025, Номер 190(1)
Опубликована: Янв. 7, 2025
Язык: Английский
Процитировано
1
Mycoses, Год журнала: 2025, Номер 68(2)
Опубликована: Фев. 1, 2025
ABSTRACT Background Post‐tuberculosis lung disease (PTLD) is a precursor to Aspergillus ‐related diseases. While Chronic Pulmonary Aspergillosis (CPA) has been extensively studied in the background of tuberculosis, Allergic Bronchopulmonary (ABPA) reported sporadically with limited information on its prevalence, clinical‐radiological features, and treatment outcomes. Objective This study, conducted high TB burden setting, aimed address this knowledge gap by systematically evaluating ABPA PTLD patients. Methods retrospective cohort study screened patients presenting respiratory or constitutional symptoms persisting for more than 3 months. The objective was report clinical‐radiological‐laboratory data, outcomes ABPA‐PTLD compared CPA (CPA‐PTLD) (PTLD only). Results Out total 1012 patients, seen 2.27%, 20.75% sensitization 0.7%. primarily presented breathlessness (91.3%) cough (82.6%) while haemoptysis (43.5%), weight loss (13%), anorexia (21.7%) were also observed, albeit less commonly CPA‐PTLD. Bronchiectasis (100%) nodules (87%) frequent whereas consolidation (21.7%), cavities (30.4%), pleural thickening (8.7%), ‘fungal ball’ (9.1%) seen, although Most received azoles (78%) as first‐line therapy, symptomatic improvement (partial/complete) observed ~78%. Conclusion may occur specific clinical (e.g., haemoptysis) radiological cavity fungal ball) features uncommon other types ABPA, but resembling conditions. Future studies should focus identifying differences natural course appropriate paradigms occurring asthma cystic fibrosis
Язык: Английский
Процитировано
1
Mycology: An International Journal on Fungal Biology, Год журнала: 2023, Номер 14(2), С. 142 - 154
Опубликована: Апрель 3, 2023
The burden of fungal infections has been on the rise globally and remains a significant public health concern in Kenya. We estimated incidence prevalence using all mycology publications Kenya up to January 2023, from neighbouring countries where data lacked. used deterministic modelling populations at risk calculate disease burden. total serious is affect 6,328,294 persons which translates 11.57% Kenyan population. Those suffering chronic such as pulmonary aspergillosis are be 100,570 people (0.2% population) probably nearly 200,000 with asthma, treatable oral antifungal therapy. Serious acute secondary HIV (cryptococcal meningitis, disseminated histoplasmosis, pneumocystis pneumonia, mucosal candidiasis) 196,543 adults children (0.4% population), while cancer-related invasive infection cases exceed 2,299 those intensive care about 1,230 incident cases, including
Язык: Английский
Процитировано
12
Open Forum Infectious Diseases, Год журнала: 2024, Номер 11(4)
Опубликована: Фев. 15, 2024
Abstract Background Chronic pulmonary aspergillosis (CPA) is an underrecognized but common complication of tuberculosis. In Nigeria, a tuberculosis-endemic country, there currently no provision to monitor the development CPA in patients treated for This study determined prevalence and incidence Lagos, Nigeria. Methods A prospective longitudinal with previously managed tuberculosis was conducted between June 2021 May 2022. The cohorts were assessed at 3-month intervals, following collected: sociodemographic data, chest radiographic findings, sputum samples fungal culture, venous blood Aspergillus immunoglobulin G estimation. cases using case definition resource-constrained countries. Descriptive inferential statistics used, significance set probability 5% (P < .05). Results Of 141 recruited, 79 (56.0%) retreatment 62 (44.0%) posttreatment group. median age (interquartile range) 40 (30–52) years, male-to-female ratio 1.1:1. Ninety-seven (69%) had GeneXpert test done, whom 63 (64.9%) negative. Cough most symptom, 15 (11%) having hemoptysis. rate increased steadily as progressed: 44 (31.2%) commencement, 45 (34.9%) 3 months, 49 (42.6%) 6 51 (54.3%) 9 months. Thus, overall 49.7%, 6.1%. Conclusions Nigeria its true burden may still be underestimated. Increased awareness posttuberculosis lung disease advocated. Evaluation should incorporated patients’ work-up
Язык: Английский
Процитировано
4
Journal of Fungi, Год журнала: 2024, Номер 10(5), С. 353 - 353
Опубликована: Май 15, 2024
The United Arab Emirates has very little data on the incidence or prevalence of fungal diseases. Using total and underlying disease risk populations likely affected proportions, we have modelled burden for first time. most prevalent serious conditions are recurrent vulvovaginitis (~190,000 affected) asthma (~34,000 affected). Given UAE’s low HIV, estimate an at-risk population 204 with respect to infections cryptococcal meningitis estimated at 2 cases annually, 15 Pneumocystis pneumonia (PCP) 20 esophageal candidiasis in HIV population. PCP non-HIV patients is 150 annually. Likewise, same tuberculosis country, a chronic pulmonary aspergillosis 1002 cases. annual invasive 505 patients, based local rates malignancy, solid organ transplantation, obstructive (5.9 per 100,000). Based 2022 report national surveillance database, candidaemia 1090 (11.8/100,000), which 49.2% occurs intensive care. Fungal diseases affect ~228,695 (2.46%) UAE.
Язык: Английский
Процитировано
4